Clesrovimab

克莱罗韦单抗

Report date: 2026/04/23 20:00:25

Base Information

Drug NameClesrovimab
Drug Alias NameClesrovimab-CFORENFLONSIAMK-1654
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionImmunostimulantsViral fusion proteins inhibitors
TargetsViral fusion proteins
Therapy Area/IndicationsLower Respiratory Tract InfectionsRespiratory Syncytial Virus InfectionsRespiratory Tract Infections
Global Approved IndicationsRespiratory Syncytial Virus Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/06/09
Country/TerritoryCzechiaBelgiumCanada +[38] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesWerthenstein Biopharma GmbhMerck Sharp & Dohme CorpMerck Sharp & Dohme Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsLower Respiratory Tract InfectionsRespiratory Syncytial Virus InfectionsRespiratory Tract Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A